While Adimmune Corp’s production of vaccines is the concern of the company and the Food and Drug Administration, vaccination policy is jointly managed by the Department of Health (DOH) and the Centers for Disease Control (CDC). The government departments that oversee production and use of vaccines are on an equal footing, neither being subordinate to the other, and the relationship between the vaccine maker and the government being one of buyer and seller.
Former health ministers have voiced their support for the government’s swine flu vaccination program — Chen Chien-jen (陳建仁) by volunteering for a flu jab and Twu Shiing-jer (涂醒哲) by saying that he hoped everyone would get vaccinated. The vaccines are supplied by two companies — Adimmune and Novartis — and they do not have the right to be partial to one or the other.
Adimmune chairman Steve Chan (詹啟賢), also a former health minister, has criticized Minister of Health Yaung Chih-liang (楊志良) for being unwilling to publish vaccine test data. This is a question of government and business taking a different approach.
When Novartis was having difficulty supplying enough vaccines to meet demand, the DOH and the CDC had no choice but to approach Adimmune as the only other possible supplier.
Now that both Novartis and Adimmune are able to supply adequate amounts of the vaccine, it is time to shore up public confidence by publishing clinical test data on the two companies’ vaccines. Novartis’ A(H1N1) vaccine test report can be found in the Sept. 11, 2009 and Dec. 31, 2009 issues of the New England Journal of Medicine.
Any adverse reactions following administration of the vaccine should be announced in a timely manner, and statistics should be compiled of mild and severe reactions.
The occurrence of severe reactions should be weighed against the death rate for A(H1N1) in the whole population (six in 100,000). If the disadvantages of immunization outweigh the advantages by a statistically significant margin, then the newly established Food and Drug Administration (FDA) should intervene and investigate. If the FDA finds this task to be beyond its limited capabilities, then it should invite experts from overseas drug administrations to help out.
In 1976, when the US instituted a program for the whole population to be vaccinated against swine flu, there were 743 cases of severe adverse reactions, including 67 deaths. The vaccination program started on Oct. 1 of that year. As severe reactions were reported one after another, and given the fact that the human mortality rate from swine flu was not as high as expected, the program was terminated on Dec. 16. A New York Times opinion piece described the affair as a “sorry debacle.”
Although science and technology are more advanced today than they were then, Adimmune should take what happened 34 years ago as a warning. The company must face the risk of allergic and autoimmune reactions such as death, semiplegia, rheumatoid arthritis and acute facial palsy and publish data about severe reactions so they can be compared with equivalent figures from the US and figures for severe reactions to the Novartis vaccine in Taiwan.
Since 1998, when I was involved in the CDC’s establishment and promotion of the flu vaccination program for people aged 65 and over, I have watched the CDC gradually mature in its efforts to prevent enterovirus and influenza.
This is borne out by public support for the CDC, which has consistently been over 80 percent throughout the past decade.
In the first month of the A(H1N1) vaccination program, which started in November, cancellations of classes and work because of swine flu outbreaks plunged 95 percent, and the number of deaths has not risen from 35. These figures indicate that the immunization policy is a wise one.
In the US, following the failure of the 1976 swine flu immunization program, the vaccine industry reviewed its work under the strengthened supervision of the US CDC, allowing it to emerge from the crisis and start anew.
The same should be done in the case of Adimmune and other vaccine makers in Taiwan. Furthermore, capital owned by political parties should not be invested in the vaccine industry; otherwise it will create a situation where those parties can control national health policy through the DOH.
The spat between Chan and Yaung should serve as a warning.
Mayo Kuo is a pediatrician.
TRANSLATED BY JULIAN CLEGG
Congressman Mike Gallagher (R-WI) and Congressman Raja Krishnamoorthi (D-IL) led a bipartisan delegation to Taiwan in late February. During their various meetings with Taiwan’s leaders, this delegation never missed an opportunity to emphasize the strength of their cross-party consensus on issues relating to Taiwan and China. Gallagher and Krishnamoorthi are leaders of the House Select Committee on the Chinese Communist Party. Their instruction upon taking the reins of the committee was to preserve China issues as a last bastion of bipartisanship in an otherwise deeply divided Washington. They have largely upheld their pledge. But in doing so, they have performed the
It is well known that Chinese President Xi Jinping’s (習近平) ambition is to rejuvenate the Chinese nation by unification of Taiwan, either peacefully or by force. The peaceful option has virtually gone out of the window with the last presidential elections in Taiwan. Taiwanese, especially the youth, are resolved not to be part of China. With time, this resolve has grown politically stronger. It leaves China with reunification by force as the default option. Everyone tells me how and when mighty China would invade and overpower tiny Taiwan. However, I have rarely been told that Taiwan could be defended to
It should have been Maestro’s night. It is hard to envision a film more Oscar-friendly than Bradley Cooper’s exploration of the life and loves of famed conductor and composer Leonard Bernstein. It was a prestige biopic, a longtime route to acting trophies and more (see Darkest Hour, Lincoln, and Milk). The film was a music biopic, a subgenre with an even richer history of award-winning films such as Ray, Walk the Line and Bohemian Rhapsody. What is more, it was the passion project of cowriter, producer, director and actor Bradley Cooper. That is the kind of multitasking -for-his-art overachievement that Oscar
Chinese villages are being built in the disputed zone between Bhutan and China. Last month, Chinese settlers, holding photographs of Chinese President Xi Jinping (習近平), moved into their new homes on land that was not Xi’s to give. These residents are part of the Chinese government’s resettlement program, relocating Tibetan families into the territory China claims. China shares land borders with 15 countries and sea borders with eight, and is involved in many disputes. Land disputes include the ones with Bhutan (Doklam plateau), India (Arunachal Pradesh, Aksai Chin) and Nepal (near Dolakha and Solukhumbu districts). Maritime disputes in the South China